AzTrials
AzTrials

StrokeCOBINCT07510633

A Mobile Brain/Body Imaging Platform for the Assessment and Optimization of Post-stroke Overground Robotic Gait Treatments

A study testing overground wearable robotic device in people with Stroke, run by Dr. Franco Molteni at 1 site in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The study aims to identify neural biomarkers that can be used to monitor the recovery of locomotion and movement of post-stroke patients, both in natural settings and with enriched treatment using robotic device. These biomarkers could potentially be utilized in clinical practice to improve recovery outcomes. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Stroke
What is being tested?
overground wearable robotic device
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteItaly
Study dates
6 May 2025to May 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years old
  • Stroke patients with different etiology: ischemic or hemorrhagic
  • Able to walk independently, eventually with aids/orthosis (FAC>2)
  • Able to give the informed consent and to comprehend the instructions necessary to complete the task
  • Subject's anthropometric parameters adequate to wear the exoskeleton;
  • Body weight < 90 kg;
Show all 10Show fewer
  • Height 150 ÷ 192 cm;
  • Thigh lenght: 355 ÷ 475 mm;
  • Calf lenght: 405 ÷ 485 mm;
  • Hip width : 690 ÷ 990 mm;

Who cannot join

  • Incapacity to give the informed consent and understand the tasks required
  • Fixed contracture at lower limbs that limits the use of the exoskeleton
  • Incapacity to walk independently (FAC<=2)
  • Subject's anthropometric parameters not adequate to wear the exoskeleton

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Franco Molteni, MD contact

+39 031 8544219

fmolteni@valduce.it

Eleonora Guanziroli, Eng contact

Italy1 site, 1 recruiting
  • Villa Beretta Rehabilitation Center

    Costa Masnaga, Lecco, 23845

    Eleonora Guanziroli, Eng, +39 0318544219, eguanziroli@valduce.it

    Recruiting

Other trials in Italy

About this study

The study aims to identify neural biomarkers that can be used to monitor the recovery of locomotion and movement of post-stroke patients, both in natural settings and with enriched treatment using robotic device. These biomarkers could potentially be utilized in clinical practice to improve recovery outcomes. Additionally, the study seeks to investigate whether it is feasible to use these biomarkers to predict the extent of recovery that patients may achieve.

Read the detailed description

To achieve efficient mobility, our brain dynamically recruits different muscle subsets to create motion strategies that allow us to move and interact with the environment. Our ability to move is a result of interactions involving processes including motivation, adaptation to changes in the environment (e.g., to cope with alterations in the terrain), distractors (e.g., walking while talking over the phone) as well as motor planning and execution. These interactions are expressed through a complex control of gait parameters including speed, rhythmicity and sequencing of muscle co-activations, as well as postural adjustments needed to meet the challenge of external events. Correct information from all the sensory systems involved is synergically needed in active behavior and postural control.

A wide range of causes such as neurological damage, traffic accidents and aging are responsible for locomotor deficits that greatly reduce the quality of life by considerably limiting everyday independence. Stroke is the second leading cause of death worldwide, with 6.7 million cases registered in 2012, and an estimated 50% of survivors suffering from permanent motor or cognitive impairments. Hemiparesis, one of the most common sequelae of stroke, is a leading cause of long-term disability, and often results in balance impairments and "foot drop", characterized by the inability to completely lift the toes off the ground during the swing phase of gait in more than 80% of stroke survivors. Stroke reduces the ability to recruit muscles and correctly perceive the body, often resulting in the learned non-use of the affected body part. The reduced capacity for information processing following stroke impairs the ability to efficiently distribute concentration to two or more tasks (dual task), with an increased difficulty with daily living activities that require performing multiple tasks simultaneously (e.g., walking and talking) .

As sensorimotor processing capabilities are disrupted, patients are not able to interact freely with the environment as all their mental energy is "usurped" by the simple act of positioning one leg after the other. They do not have the "mental bandwidth" that we normally take for granted and that allows us for example to have a pleasant conversation with other people who are walking with us. In fact, due to the loss of physical and mental bandwidth under dual-task conditions, stroke survivors often experience falls, leading to a lack of confidence, anxiety and in some cases agoraphobia. They are also likely to experience decreased motivation and engagement in the recovery treatment, often spiraling towards a vicious circle detrimental to the success of any rehabilitation therapy attempted.

Gait impairment is considered to be one of the most serious disabling sequelae of stroke, as one of the primary goals of patients is being able to walk and manage daily-life activities independently. Stroke induces modifications in locomotion, which is the primary means of daily management of mobility. Gait rehabilitation is thus the primary goal of post-stroke rehabilitation, especially given its close relation to cognitive impairment. Given the constant increase of people requiring rehabilitation or assistance treatment every year and the ever-increasing choice of treatments available, the assessment and development of suitable personalized strategies to address gait impairments is now an impending priority.

Unfortunately, rehabilitation outcomes are often uncertain as they are associated with motivation, engagement and attention. Patients' engagement, in fact, will determine the effectiveness of the therapy to engage motor learning (i.e., recognition of the discrepancy between actual and expected outcomes during error-driven learning), which is an essential prerequisite for adaptation (i.e., modification of a movement, trial by trial, based on error feedback).

In short, rehabilitation must be performed in a closed-loop fashion, where patients are actively involved in the rehabilitation therapy or even have a measure of control over it while receiving feedback and "rewards" that can promote sensorimotor integration and multisensory processing in the Central Nervous System (CNS). Rehabilitation acts on the mechanisms of brain plasticity, that is the intrinsic capacity of the brain to react as a highly dynamic system that can change the properties of its neural circuits. Reorganization of surviving CNS elements supports behavioral recovery, for example, through changes in interhemispheric lateralization, activity of association cortices linked to injured zones, and organization of cortical representational maps. Human-in-the-loop rehabilitation, by acting on the mechanisms of error-based and reward-based learning, can direct reorganization much more effectively towards increasing the representation of sensorimotor maps, partially (if not completely) lost after a Stroke.

Conventional movement rehabilitation is mainly based on therapists' direct observation and mobilization of lower limbs, followed by assisted gait over ground, either passive or active, using context-specific motor tasks and related feedback. In "neurophysiological" techniques, the physiotherapist, based on neurophysiological knowledge of gait principles, acts as "problem solver" and "decision maker", with the patient acting as a passive recipient. In "motor learning" techniques on the other hand active patient involvement is required together with neuropsychological evaluation. To enhance patients' engagement, standardization and therapy effectiveness, enriched motor learning neurophysiological treatments that include robotic assistive devices (exoskeletons) may be used.

Over the past 20 years, an overwhelming number of combinations of enriched and conventional treatments has been proposed to increase patients' motivation with interactive biofeedback or by giving patients a measure of control over the assisting robotic devices. Despite an intense debate on the merits of each solution, however, there is still insufficient evidence to clearly indicate which approach is most effective (and most importantly, why) in promoting gait recovery after stroke. In fact, we still lack the knowledge needed to apply such technology in the best possible way in relation to the individual patient's condition, especially in the case of gait rehabilitation.

In the last few years Mobile Brain/Body Imaging (MoBI) has gained momentum among the scientific community as an emerging paradigm to jointly study brain and behavior and especially locomotion, also outside laboratory settings. MoBI can be used to provide the clinician with useful information to assess the rehabilitation progress by "encoding" the neural correlates of gait by means of brain-muscle connectivity assessment during movement rather than before/after the task as in current practice. Real-time MoBI may also be used to decode patient's intention of movement based on which to perform stimulus delivery (e.g., through FES, exoskeletons etc.), thus increasing engagement and promoting plastic reorganization. Successful development of MoBI setups is however still a technological challenge. Neuroimaging techniques are either not portable (e.g., Magnetic Resonance, Magnetoencephalography), or lack the temporal resolution necessary to capture near-instantaneous intra-stride modulations of neural activity during locomotion (e.g., functional near-Infrared Spectroscopy - fNIRS) because of the variation speed of the physiological marker they use (e.g., blood oxygen level for fNIRS). Electroencephalography (EEG) is the only technique that is portable enough, non-invasive and with the temporal resolution necessary to detect even such modulations of brain activity during walking. However, the EEG is highly sensitive to movement artifacts and requires solving key technological challenges and developing complex and often discouraging analysis pipelines. In any case, MoBI with EEG, though challenging, is not impossible: to date, several authors showed gait-phase-related intra-stride patterns of activation and deactivation e.g., also demonstrating a directional link between sensorimotor cortical areas and leg muscles during stereotyped gait, but studies of gait rehabilitation with MoBI neuromuscular assessment in natural ecological conditions are still critically missing. Also, the following technical/scientific question remains: "how can we distinguish movement-related neural activity from movement and mechanical artifacts? Atalante X: a disruptive wearable powered cobot. It is a collaborative exoskeleton that enables patients with severe gait impairment, including those with upper extremity dysfunction or cognition challenges to stand up and walk hands-free; it is the only cobot equipped with 12 engines at hip, knee and ankle level that allows human being to transform the intention of movement into actual movement.

The project aims to optimize ATALANTE X cutting edge hi-tech solutions personalizing rehabilitation gait treatment of stroke patients using:

  1. Characterization of patient's Cognitive Flexibility using Dessintey system. Dessintey is a unique technology dedicated to motor planning and central control of movement based on visuomotor simulation training that combines Action Observation-Motor Imaging-Mirror Therapy approaches. In fact, every time a movement is observed, the brain simulates instantly and without effort this same movement; in this way it is possible to increase imagination and body perception.
  2. Monitoring and evaluation of Human-Cobot interaction using disruptive dynamic EEG-EMG neural biomarkers using Mobile Brain/Body Imaging (MoBI)
Conditions
Stroke
Being tested
overground wearable robotic device
Keywords
Stroke, Overground wearable robotic device, EEG, EMG, Ground Reaction
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • overground wearable robotic deviceDevice

    To provide a complete overview of the complex system patient-technology, motor and cognitive evaluations, commonly used in daily clinical practice, will be performed at pre-treatment time (T0), after 12 sessions of treatment (T1) and one month follow-up time (T2). The first (E1) and the last session (E12) of treatment will be instrumented with EEG, EMG and GRF which will collect data.

Study groups in NCT07510633
Study groupRoleWhat they receive
Post stroke patients in chronic condition using overground wearable robotic deviceExperimentalTraining with overground wearable robotic device for 12 sessions
Receives: Device: overground wearable robotic device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Motor Outcome Measure

    Trunk Control Test (TCT) [0-100]

    Measured: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up

  2. Motor Outome Measure

    6-minute walking Test (6mWT)

    Measured: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up

  3. Motor Outcome Measure

    10 Meter Walk Test (10MWT)

    Measured: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up

  4. Motor Outcome Measure

    Berg Balance Scale (BBS) [0-56]

    Measured: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up

  5. Motor Outcome Measure

    Motricity Index (MI) at lower limb [0-100]

    Measured: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up

  6. Motor outcome measure

    5 times Sit-to-Stand (5XSST)

    Measured: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up

  7. Motor Outcome Measure

    Modified Ashworth Scale (MAS) at lower limb

    Measured: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up

  8. Motor oucome measure

    Functional Ambulation Category (FAC) [0-5]

    Measured: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up

  9. Biomarkers

    Cortico-cortico coherence from EEG

    Measured: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up

  10. Biomarkes

    Cortico-muscular coherence EEG-EMG

    Measured: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up

  11. Biomarkers

    Ground reaction forces during foot-ground interaction

    Measured: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Apr 2026
  2. Study start6 May 2025
  3. Primary completionMay 2027 (estimated)
  4. Study completionMay 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Control subjects will be age-matched healthy subjects recruited within the pool of clinicians/therapists already working at the clinic. They will be used to collect normative data on the complexity of brain activity.
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07510633
Sponsor's protocol ID
COBI
Acronym
COBI
Status last verified
Mar 2026
First submitted
5 Mar 2026
Last updated
3 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing overground wearable robotic device in people with Stroke, run by Dr. Franco Molteni at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Franco Molteni, MD (+39 031 8544219, fmolteni@valduce.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Motor Outcome Measure (time frame: From enrollment to the end of treatment at 4 weeks + 4 weeks follow-up). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in